Non‐canonical cMet regulation by vimentin mediates Plk1 inhibitor–induced apoptosis
Ratnakar Singh(University of Illinois Urbana-Champaign), Faye M. Johnson(The University of Texas MD Anderson Cancer Center), Bingliang Fang(The University of Texas MD Anderson Cancer Center), Vaishnavi Sambandam(National Comprehensive Cancer Network), Xiayu Rao(The University of Texas MD Anderson Cancer Center), Jing Wang(The University of Texas MD Anderson Cancer Center), Li Shen(The University of Texas MD Anderson Cancer Center), Shaohua Peng(Sinochem Group (China)), Pavitra Viswanath(The University of Texas MD Anderson Cancer Center)
Cited by 28
Related Papers
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
|Cancer Cell|2021|930
Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas
|Cell Reports|2018|366
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
|Cancer Discovery|2023|181
Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates
|Nature Communications|2016|159